NORSWITCH Results Concerning In Crohns Disease Says Janssen
Janssen Biotech says that the NORSWITCH study on switching from Remicade to biosimilar infliximab raises significant questions over safety and...&160;&160;
View ArticleTrump Congress And The Future Of ValueBased Drug Contracting
CMSdriven experiments in valuebased purchasing may slow in the new US administration but commercial pressures to price drugs according to...&160;&160;&160;
View ArticleOTC Drug Industry Could Stand To Gain With &39;Pragmatist&39; In White House
With the Trump administration ahead CHPA&39;s highest regulatory priorities include eliminating a requirement from the Obama era that consumers get...&160;&160;&160;&
View ArticleA Patient With Endoscopic Recurrence of Crohn Disease
A 24yearold man with a history of Crohn disease is asymptomatic but a routine surveillance ileocolonoscopy shows endoscopic recurrence. How would you manage this patient Medscape Gastroenterology
View ArticleTampa Medical Marijuana Conference Follows Legalization in Florida
TAMPA Fla. Nov. 13 2016 PRNewswire CannaCure Florida is proudly offering the most comprehensive medical cannabis educational conference following passage of Florida Amendment 2 legalizing medical...
View ArticleAbbVie's HUMIRAÂ Adalimumab Receives CHMP Positive Opinion to Treat...
NORTH CHICAGO Ill. Nov. 14 2016 PRNewswire AbbVie NYSE ABBV a global biopharmaceutical company today announced that the Committee for Medicinal Products for Human Use CHMP of the European Medicines...
View ArticleNew Phase 3 Data Show SIMPONI ARIAÂ golimumab Significantly Improved Signs...
WASHINGTON Nov. 14 2016 PRNewswire Janssen Research & Development LLC Janssen announced today new findings from a pivotal Phase 3 study showing the efficacy and safety profile of the...
View ArticleTwo Studies Reveal Differences In RealWorld Treatment Patterns In Rheumatoid...
WASHINGTON Nov. 14 2016 PRNewswire Janssen Biotech Inc. announced today findings from two claims database studies examining treatment patterns in patients with rheumatoid arthritis RA. The first study...
View ArticleNektar Therapeutics to Present at Jefferies 2016 Global Healthcare Conference...
SAN FRANCISCO Nov. 11 2016 PRNewswire Nektar Therapeutics Nasdaq NKTR today announced that the company will be webcasting its corporate presentation at the Jefferies 2016 London Healthcare Conference...
View ArticleEuropean Commission Approves Stelara for Adults with Crohns Disease
NewsEuropean Commission approves Stelara ustekinumab for treatment of adults with moderately to severely active Crohns disease.
View ArticleRedHill Biopharma Reports 2016 Third Quarter Financial Results
RedHill maintains a debtfree balance sheet with $40.5 million in cash at the end of the third quarter allowing the Company to continue to diligently execute its three ongoing Phase III gastrointestinal...
View ArticleProtagonist Therapeutics Reports Third Quarter 2016 Financial Results and...
MILPITAS Calif. Nov. 14 2016 PRNewswire Protagonist Therapeutics Inc. NASDAQ PTGX today reported its financial results for the quarter ended September 30 2016 and provided an update on the company's...
View ArticleManagement of Ileocolonic Anastomotic Strictures in Crohn Disease
Endoscopic balloon dilation can be used to delay surgery in eligible patients with lessactive disease.
View ArticleJanssens Stelara cleared to treat Crohns disease
Certain patients with Crohn's disease have gained the potential to access a new treatment option in Europe with the expanded approval of Janssen's psoriasis blockbuster Stelara.
View ArticleEU approves Janssen's treatment for Crohn's disease
Janssen's Stelara or ustekinumab has been approved by the European Commission as a treatment for moderately to severely act More
View ArticleUstekinumab Is Approved for Crohn Disease
Ustekinumab is superior to placebo in achieving induction response and maintaining remission in severely to moderately active Crohn disease.
View ArticleNew Test for Inflammatory Bowel Disease Cleared by FDA
SAN DIEGO Nov. 16 2016 PRNewswire Inova Diagnostics a worldwide leader in autoimmune diagnostic reagents and systems for the clinical laboratory is pleased to announce the US Food and Drug...
View ArticleU.S. IVD And LDT for Autoimmune Diseases Market Worth $4745.4 Million By 2024...
SAN FRANCISCO November 16 2016 PRNewswire The U.S. IVD for autoimmune diseases market was valued at USD 4.0 billion in 2015 and is expected to reach a value of USD 4.74 billion by 2024 .The U.S....
View ArticleJanssen's Crohn's treatment licensed for UK use
Janssen a subsidiary of Johnson & Johnson has announced that its treatment Stelara ustekinumab is now licensed by the European Commission for use in the UK as an option for moderate to severely...
View ArticleAmpio Pharmaceuticals Inc. AMPE Medical Equipment Deals and Alliances Profile...
SummaryAmpio Pharmaceuticals Inc. Ampio formerly Chay Enterprises Inc. is a biopharmaceutical company that discovers and develops novel therapeutic candidates for inflammatory conditions. The company...
View Article